Press Releases

EndoBarrier® Study in Morbidly Obese Adolescents Completes Enrollment

First study of EndoBarrier in adolescents completed at University Children’s Hospital (UCH) in Ljubljana, Slovenia Preliminary data show BMI reduced by 10 percent Acceptable safety profile and improvement in metabolic parameters BOSTON and SYDNEY — 16 February 2017 — GI Dynamics, Inc. (ASX:GID), a...

read more

GI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review

BOSTON and SYDNEY — 11 January 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today released a 2017 business outlook and recap of 2016 accomplishments. 2017 marks the first full calendar...

read more
Page 3 of 3123